Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
NCT ID: NCT02831179
Last Updated: 2017-09-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE1
Study Classification
INTERVENTIONAL
Study Start Date
2017-12-31
Study Completion Date
2020-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually cannot be cured or controlled with treatment, has returned after a period of improvement, and cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with capecitabine and temozolomide in patients with advanced well-differentiated neuroendocrine tumors.
SECONDARY OBJECTIVES:
2\. To determine the safety profile of the combination of capecitabine, temozolomide and veliparib in patients with advanced well-differentiated neuroendocrine tumors (NET).
3\. To evaluate the antitumor activity of the combination of capecitabine, temozolomide and veliparib in advanced well-differentiated NET patients
4\. To determine progression-free survival (PFS) of the combination of capecitabine, temozolomide, and veliparib in advanced well-differentiated NET patients IV. To evaluate the association between pharmacodynamic biomarkers and response in patients with advanced well-differentiated NET patients.
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
I. To determine the maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with capecitabine and temozolomide in patients with advanced well-differentiated neuroendocrine tumors.
SECONDARY OBJECTIVES:
2\. To determine the safety profile of the combination of capecitabine, temozolomide and veliparib in patients with advanced well-differentiated neuroendocrine tumors (NET).
3\. To evaluate the antitumor activity of the combination of capecitabine, temozolomide and veliparib in advanced well-differentiated NET patients
4\. To determine progression-free survival (PFS) of the combination of capecitabine, temozolomide, and veliparib in advanced well-differentiated NET patients IV. To evaluate the association between pharmacodynamic biomarkers and response in patients with advanced well-differentiated NET patients.
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Functional Pancreatic Neuroendocrine Tumor
Malignant Somatostatinoma
Merkel Cell Carcinoma
Metastatic Adrenal Gland Pheochromocytoma
Metastatic Carcinoid Tumor
Multiple Endocrine Neoplasia Type 1
Multiple Endocrine Neoplasia Type 2A
Multiple Endocrine Neoplasia Type 2B
Neuroendocrine Neoplasm
Non-Functional Pancreatic Neuroendocrine Tumor
Pancreatic Glucagonoma
Pancreatic Insulinoma
Recurrent Adrenal Cortex Carcinoma
Recurrent Adrenal Gland Pheochromocytoma
Recurrent Merkel Cell Carcinoma
Somatostatin-Producing Neuroendocrine Tumor
Stage III Adrenal Cortex Carcinoma
Stage III Thyroid Gland Medullary Carcinoma
Stage IIIA Merkel Cell Carcinoma
Stage IIIB Merkel Cell Carcinoma
Stage IV Adrenal Cortex Carcinoma
Stage IV Merkel Cell Carcinoma
Stage IVA Thyroid Gland Medullary Carcinoma
Stage IVB Thyroid Gland Medullary Carcinoma
Stage IVC Thyroid Gland Medullary Carcinoma
Thymic Carcinoid Tumor
VIP-Producing Neuroendocrine Tumor
Well Differentiated Adrenal Cortex Carcinoma
Zollinger Ellison Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (capecitabine, temozolomide, veliparib)
Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
Group Type
EXPERIMENTAL
Capecitabine
Intervention Type
DRUG
Given PO
Temozolomide
Intervention Type
DRUG
Given PI
Veliparib
Intervention Type
DRUG
given PO
Pharmacological Study
Intervention Type
OTHER
Correlative studies
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capecitabine
Given PO
Intervention Type
DRUG
Temozolomide
Given PI
Intervention Type
DRUG
Veliparib
given PO
Intervention Type
DRUG
Pharmacological Study
Correlative studies
Intervention Type
OTHER
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathologically confirmed metastatic unresectable well differentiated (low grade and intermediate grade) neuroendocrine tumors (Ki-67 \< 20% and mitotic rate \< 2 per 10 high power field) that demonstrate progressive disease (by serial computed tomography \[CT\] or magnetic resonance imaging \[MRI\] scans) in past 12 months including
* Carcinoid tumors originating anywhere in the body including the gastrointestinal (GI) tract or bronchial tree or thymus
* Pancreatic neuroendocrine tumors (including functional and non-functional islet cell, insulinomas and glucagonomas)
* Pheochromocytomas
* Gastrinomas (Zollinger-Ellison syndrome)
* Multiple endocrine neoplasia (MEN type I/II),
* Adrenal carcinomas with NET markers by immunohistochemistry (IHC) or serum
* Somatostatinoma
* VIPoma (vasoactive intestinal peptide)
* Merkel cell tumors
* Medullary thyroid carcinoma
* Neuroendocrine tumors of unknown primary site
* Patients must have progressed on octreotide therapy and/or radioactive isotopes linked to octreotide or its congeners if they had a positive octreotide scan; patients who have negative or mildly positive octreotide scans are exempt from this requirement
* Somatostatin analogs can be continued at their tolerated dose in patients with functional symptoms related to underlying disease such as in functional islet cell, insulinomas, glucagonomas etc
* Patients may have received prior chemotherapy for advanced disease including either capecitabine or temozolomide single agent as long as it did not include combination of capecitabine and temozolomide
* Patients must have completed prior (non-excluded) anti-cancer therapy (including surgery or chemotherapy or hepatic embolization/chemoembolization or radioactive isotopes i.e. yttrium 90) at least 4 weeks prior to day 1
* Patients with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease and have not had treatment with steroids within 1 week of study enrollment
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Anticipated life expectancy of greater than 3 months
* Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response
* Granulocytes \> 1,500/ml
* Platelets \> 100,000/ml
* Hemoglobin \>= 10 g/dl
* Creatinine \< 1.5 x upper limit of normal (ULN) or creatinine clearance \>= 50 mL/min/1.73 m\^2 for subjects with creatinine levels above institutional normal
* Bilirubin \< 1.5 x ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN (\< 5 x ULN if liver metastases are present)
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of veliparib, capecitabine and temozolomide administration
* Ability to understand and the willingness to sign a written informed consent document
* Patients must be able to swallow pills
* Carcinoid tumors originating anywhere in the body including the gastrointestinal (GI) tract or bronchial tree or thymus
* Pancreatic neuroendocrine tumors (including functional and non-functional islet cell, insulinomas and glucagonomas)
* Pheochromocytomas
* Gastrinomas (Zollinger-Ellison syndrome)
* Multiple endocrine neoplasia (MEN type I/II),
* Adrenal carcinomas with NET markers by immunohistochemistry (IHC) or serum
* Somatostatinoma
* VIPoma (vasoactive intestinal peptide)
* Merkel cell tumors
* Medullary thyroid carcinoma
* Neuroendocrine tumors of unknown primary site
* Patients must have progressed on octreotide therapy and/or radioactive isotopes linked to octreotide or its congeners if they had a positive octreotide scan; patients who have negative or mildly positive octreotide scans are exempt from this requirement
* Somatostatin analogs can be continued at their tolerated dose in patients with functional symptoms related to underlying disease such as in functional islet cell, insulinomas, glucagonomas etc
* Patients may have received prior chemotherapy for advanced disease including either capecitabine or temozolomide single agent as long as it did not include combination of capecitabine and temozolomide
* Patients must have completed prior (non-excluded) anti-cancer therapy (including surgery or chemotherapy or hepatic embolization/chemoembolization or radioactive isotopes i.e. yttrium 90) at least 4 weeks prior to day 1
* Patients with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease and have not had treatment with steroids within 1 week of study enrollment
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Anticipated life expectancy of greater than 3 months
* Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response
* Granulocytes \> 1,500/ml
* Platelets \> 100,000/ml
* Hemoglobin \>= 10 g/dl
* Creatinine \< 1.5 x upper limit of normal (ULN) or creatinine clearance \>= 50 mL/min/1.73 m\^2 for subjects with creatinine levels above institutional normal
* Bilirubin \< 1.5 x ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN (\< 5 x ULN if liver metastases are present)
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of veliparib, capecitabine and temozolomide administration
* Ability to understand and the willingness to sign a written informed consent document
* Patients must be able to swallow pills
Exclusion Criteria
* Prior chemotherapy with combination of capecitabine (or 5-flourouracil \[5-FU\]) "and" temozolomide (or dacarbazine \[DTIC\]) will be excluded; patients can have had prior therapies up to 3 prior chemotherapy regimens such as streptozocin, anthracyclines, irinotecan, etoposide, or a platinum agent including single agent capecitabine (or 5FU) or temozolomide (or DTIC).
* History of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)
* Patients who have active or uncontrolled infection or serious medical or psychiatric illness preventing informed consent or on intensive treatment
* Patients with brain metastases are excluded
* Patients with uncontrolled seizures or any neurological conditions resulting in increased risk for seizures are not eligible for study entry
* Patients with documented central nervous system (CNS) ischemia and/or infarction, whether symptomatic or discovered incidentally without clinical symptoms, will be excluded from study participation
* Patients with a history of the arterial or venous thromboembolism within =\< 12 months of study entry are not eligible
* Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are excluded from the study
* Patients with another active malignancy within the past five years except for carcinoma in situ of cervix or in situ carcinoma of the bladder or non-melanomatous carcinoma of the skin
* Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities
* Patients who are receiving any other investigational agents
* Major surgical procedure within 4 weeks of treatment
* Patients may not have any clinically significant cardiovascular disease including the following:
* Myocardial infarction or ventricular tachyarrhythmia within 6 months
* Prolonged QTc \> 480 msec at baseline
* Symptomatic congestive heart failure (CHF) of New York Heart Association (NYHA) functional class \>= 3
* Major conduction abnormality (unless a cardiac pacemaker is present)
* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparib
* History of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)
* Patients who have active or uncontrolled infection or serious medical or psychiatric illness preventing informed consent or on intensive treatment
* Patients with brain metastases are excluded
* Patients with uncontrolled seizures or any neurological conditions resulting in increased risk for seizures are not eligible for study entry
* Patients with documented central nervous system (CNS) ischemia and/or infarction, whether symptomatic or discovered incidentally without clinical symptoms, will be excluded from study participation
* Patients with a history of the arterial or venous thromboembolism within =\< 12 months of study entry are not eligible
* Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are excluded from the study
* Patients with another active malignancy within the past five years except for carcinoma in situ of cervix or in situ carcinoma of the bladder or non-melanomatous carcinoma of the skin
* Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities
* Patients who are receiving any other investigational agents
* Major surgical procedure within 4 weeks of treatment
* Patients may not have any clinically significant cardiovascular disease including the following:
* Myocardial infarction or ventricular tachyarrhythmia within 6 months
* Prolonged QTc \> 480 msec at baseline
* Symptomatic congestive heart failure (CHF) of New York Heart Association (NYHA) functional class \>= 3
* Major conduction abnormality (unless a cardiac pacemaker is present)
* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparib
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Vanderbilt-Ingram Cancer Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jordan Berlin, MD
Professor of Medicine
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jordan Berlin, M.D.
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2016-01044
Identifier Type: REGISTRY
Identifier Source: secondary_id
VICC GI 14134
Identifier Type: -
Identifier Source: org_study_id